Reata Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Reata Pharmaceuticals (RETA) IPO Opens Flat
May 26, 2016 10:39 AM EDTToday's IPO for Reata Pharmaceuticals, Inc. (Nasdaq: RETA) opened for trading at $11.06 after pricing 5,500,000 shares of its Class A common stock at $11.00 per share. The company was recently looking to offer 4 million shares and expected a pricing range of $14 - $16 per... More
